Direct costs associated with the disease management of patients with unresectable advanced non-small-cell lung cancer in The Netherlands

Lung Cancer

Volumn 64, Issue 1, 2009, Pages 110-116

  Pompen, Marjolein ^a   Gok, Murat ^b   Novák, Annoesjka ^a   van Wuijtswinkel, Rob ^a   Biesma, Bonne ^c   Schramel, Franz ^d   Stigt, Jos ^e   Smit, Hans ^f   Postmus, Pieter ^b  

^a Roche Netherlands BV   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c JEROEN BOSCH HOSPITAL   (Netherlands)

^d ST ANTONIUS HOSPITAL   (Netherlands)

^e ISALA HOSPITAL   (Netherlands)

^f RIJNSTATE HOSPITAL   (Netherlands)

Author keywords

Costs; Disease management; Guidelines; Medical chart review; Non small cell lung cancer; Observational data; The Netherlands

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; NAVELBINE; PACLITAXEL; VINFLUNINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; COST OF ILLNESS; COST UTILITY ANALYSIS; FEMALE; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; INTERMETHOD COMPARISON; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; METASTASIS; MONEY; MULTIPLE CYCLE TREATMENT; NETHERLANDS; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE MANAGEMENT; FEMALE; HOSPITAL COSTS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NETHERLANDS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 61549111592     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2008.07.009     Document Type: Article

References (21)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Estimating the world cancer burden; Globocan. Int J Cancer 94 2 (2001) 153-156
2. Kanker in Nederland: trends en prognoses. www.kwfkankerbestrijding.nl; 2004 (accessed on 26.03.2008).
3. Cijfers over longkanker. http://www.rivm.nl/vtv/object_class/kom_longkanker.html; (accessed on 04.04.2008).
4. Damhuis R.A.M., and Schutte P.R. Resection rates and post-operative mortality in 7,899 patients with lung cancer. Eur Respir J 9 1 (1996) 7-10
5. Janssen-Heijnen M.L., Schipper R.M., Razenberg P.P., Crommelin M.A., and Coebergh J.W. Prevalence of co-morbidity in lung cancer patients and its relationship with treatment: a population based study. Lung Cancer 21 2 (1998) 105-113
6. Vereniging van Integrale kankercentra/Kwaliteitsinstituut voor de gezondheidszorg CBO. Richtlijn niet klein-cellig longcarcinoom: stadiering en behandeling. Alphen aan den Rijn: Van Zuiden Communications; 2004. http://www.cbo.nl/product/richtlijnen/folder20021023121843/longc-rl-2004 .pdf (accessed on 04.04.2008).
7. van Meerbeeck J.P., Koning C.C., Tjan-Heijnen V.C., Boekema A.G., Kaandorp C.J., and Burgers J.S. Richtlijn, 'Niet-kleincellig longcarcinoom; stadiering en behandeling'. Ned Tijdschr Geneeskd 149 2 (2005) 72-77
8. Pfister D.G., Johnson D.H., Azzoli C.G., Sause W., Smith T.J., Baker Jr. S., et al. American society of clinical oncology treatment of unresectable non-small-cell lung cancer guideline; update 2003. J Clin Oncol 2 22 (2004) 330-353
9. Evans T. Chemotherapy in advanced non-small cell lung cancer. Semin Respir Crit Care Med 26 3 (2005) 304-313
10. Shepherd F.A., Dancey J., Ramlau R., Mattson K., Gralla R., O'Rourke M., et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell-lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18 10 (2000) 2095-2103
11. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353 2 (2005) 123-132
12. Hanna N., Shepherd F.A., Fossella F.V., Pereira J.R., De Marinis F., von Pawel J., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22 9 (2004) 1589-1597
13. Oostenbrink JB, Bouwmans CAM, Koopmanschap MA, Rutten FFH. Handleiding voor kostenonderzoek, methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg. College voor zorgverzekeringen. Geactualiseerde versie; 2004.
14. Molinier L., Combescure C., Chouaïd C., Daurès J.P., Housset B., Fabre D., et al. Cost of lung cancer-a methodological review. Pharmacoeconomics 24 7 (2006) 651-659
15. Evans W.K., Will B.P., Berthelot J.M., and Wolfson M.C. The cost of managing lung cancer in Canada. Oncology (Williston Park) 9 Suppl. 11 (1995) 147-153
16. Dedes K.J., Szucs T.D., Bodis S., Joerger M., Lowy A., Russi E.W., et al. Management and costs of treating lung cancer patients in a university hospital. Pharmacoeconomics 22 7 (2004) 435-444
17. Wolstenholme J.L., and Whynes D.K. The hospital costs of treating lung cancer in the United Kingdom. Br J Cancer 80 1-2 (1999) 215-218
18. Braud A.C., Lévy-Piedbois C., Piedbois P., Piedbois Y., Livartovski A., Le Vu B., et al. Direct treatment costs for patients with lung cancer from first recurrence to death in France. Pharmacoeconomics 21 9 (2003) 671-679
19. Vergnenegre A., Molinier L., Combescure C., Daures J.P., Housset B., and Chouaid C. The cost of lung cancer management in France from the payor's perspective. Dis Manage Health Outcomes 14 1 (2006) 55-67
20. Polder J.J., Barendregt J.J., and van Oers H. Health care costs in the last year of life-the Dutch experience. Soc Sci Med 63 7 (2006) 1720-1731
21. Slobbe LCJ, Kommer GJ, Smit JM, Groen J, Meerling WJ, Polder JJ. Costs of illness in the Netherlands 2003 RIVM rapport nr. 270751010. Bilthoven: RIVM; 2006. http://www.rivm.nl/bibliotheek/rapporten/270751010.html (accessed on 04.04.2008).